September 22nd 2021, 3:00pm
The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.
September 1st 2021, 10:29pm
The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.
December 17th 2020, 4:00pm
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
December 6th 2020, 7:30pm
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
June 25th 2018, 6:50pm
The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Sometime Risk for Breast Cancer is All in the Family
Cancer Survivors Can Get Tired of Being Called ‘Strong’
‘Key Signs’ of Cytokine Release Syndrome to Know
FDA Grants Fast Track Designation to CTX-009 in Biliary Tract Cancer